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Low-Penetrance Branches in Matrilineal Pedigrees
with Leber Hereditary Optic Neuropathy
To the Editor:
Leber hereditary optic neuropathy (LHON; MIM
535000) is an inherited form of bilateral optic atrophy
in which the primary etiologic event is a mutation in the
mitochondrial genome (reviewed by Riordan-Eva et al.
1995; Nikoskelainen et al. 1996; Howell 1997a, 1997b).
It has been recognized, since the earliest studies of
LHON (Leber 1871), that the penetrance is incomplete.
It is now understood that this incomplete penetrance
reflects a complex etiology and that multiple secondary
factors modify or determine the manifestation of the
optic neuropathy in LHON (reviewed by Howell 1997a,
1997b).
The identification of these secondary etiologic factors
has been difficult, but heavy smoking and alcohol con-
sumption have received epidemiological support (e.g.,
see Johns 1994). It appears, however, that there are nu-
merous, but poorly defined, physiological, environmen-
tal, societal, and demographic “life style” factors that
modify the risk of optic neuropathy. For example, there
has been a relatively recent (i.e., during the second half
of this century) parallel decline in penetrance among
Australian LHON families and in the incidence of a
pathologically similar, acquired optic-nerve disorder, to-
bacco-nutritional amblyopia. This trend suggests that
there is a common factor in their etiology (Mackey and
Howell 1994). In addition, penetrance in LHON fam-
ilies from different northern European countries varies
more than twofold (e.g., see Mackey et al. 1996). Even
within a single country, such as Australia, there are sub-
stantial penetrance differences among 11778 LHON
families (Howell et al. 1993).
We have been analyzing penetrance in large, multi-
generation Australian and British LHON families, as one
approach to the elucidation of these secondary etiologic
factors. A previously undescribed pattern of results was
obtained during this survey, and we describe here the
occurrence of distinct low- (and high-) penetrance
branches in LHON pedigrees.
The TAS1 LHON family is the largest matrilineal ped-
igree that has been assembled. It spanned 11 generations
by the early 1990s, and it now comprises 11,600 ma-
ternally related individuals, all of whom are descended
from a woman who was born in 1777 (III-12 in fig. 1;
also see Mackey and Buttery 1992). This LHON family
carries the primary mutation at nucleotide 11778 of the
mitochondrial ND4 gene (Mackey 1994). Because this
family has been located within a relatively small geo-
graphical area, because of the good clinical record keep-
ing, and because of the high level of compliance and
cooperation on the part of the family, we are confident
about the identification of affected and unaffected family
members. However, there is an inherent uncertainty in
all studies of LHON penetrance, which results from the
variable and unpredictable age at onset, spanning the
1st through 8th decades, with a mean in the mid 20s
(e.g., see Riordan-Eva et al. 1995; Nikoskelainen et al.
1996). Therefore, LHON carriers (especially males) are
always at risk, and there is no age at which one can
state with absolute confidence that a family member will
remain unaffected.
To control, as much as possible, for the confounding
factors in the analysis of penetrance, we have applied
the following guidelines. In the first place, we limited
our penetrance calculations tomaleswhowere 130 years
of age, to include only those individuals who were past
the age of maximum risk. The number of affected fe-
males is generally too low, even in the largest LHON
families, to provide robust information on penetrance,
and they were excluded from the present study. Second,
we define here “affected” and “unaffected” in terms of
a significant vision loss whose characteristics are com-
patible with LHON. There are subtle, subclinical
Letters to the Editor 1221
Figure 1 High- and low-penetrance branches in the TAS1
11778-mutation LHON family. This partial pedigree has been drawn
to show the genealogical origin of the branches in which there is an
unusually low (L1–L4) or high (H1 and H2) penetrance of the optic
neuropathy in male family members. Some of the female origins of
family branches are shown, with pedigree designations that follow
standard numbering schemes (in which the generation designation is
denoted by a Roman numeral). The fractions beneath the low- and
high-penetrance branches refer to the number of affected (numerator)
and total (denominator) males within that particular branch.
changes in the eye (most prevalently, a microangiopathy;
see the discussion in Riordan-Eva et al. 1995; Nikoske-
lainen et al. 1996) that are found at high frequency in
LHON family members, but these are not considered
here. Ongoing clinical studies of the TAS1 LHON family
give no indication that the present results are biased by
a high frequency of atypical or unreported ophthal-
mological abnormalities. Finally, significant recovery of
vision is very rare in 11778-mutation LHON patients
(reviewed in Howell 1997a, 1997b), and there is no
indication that the penetrance frequencies in the TAS1
LHON family have been biased by this phenomenon.
Analysis of the TAS1 pedigree revealed that there are
low-penetrance four branches (designated “L1”–“L4”),
in which the penetrance of the optic neuropathy has
essentially dropped to zero (fig. 1). A branch is defined
here as the descendants of any female in a matrilineal
pedigree; the descendants span at least four generations,
to provide sufficient information for the determination
of penetrance. There is only a single affectedmale among
the L1, L2, L3, and L4 branches, which include a total
of 17, 43, 22, and 24 males, respectively. This individual
lost vision soon after suffering head trauma in an au-
tomobile accident, a severe precipitating factor. For com-
parison, we ascertained the penetrance in the more typ-
ical (designated here as “medium-penetrance”) branches
of the pedigree. Whereas the L2 branch (which starts
with female VI-18) contained 1 affected male among a
total of 43, there were 9 affected males, among a total
of 53, in the branch that descended from female V-7 and
that spans generations VI–IX (this female is not desig-
nated in fig. 1). This difference in penetrance frequencies
is statistically significant ( ; 2#2 x2 test, adjustedP ! .05
for continuity). These statistical tests must be treated
with caution, however, because it is difficult to rule out
post hoc bias in the identification of low-penetrance
branches. We attempted to address this concern by fur-
ther analysis of penetrance in the TAS1 pedigree. Thus,
the L4 branch is one of several branches that descend
from female V-1, and the penetrance is ∼12% among
males in the other branches that descend from her. In a
similar fashion, the penetrance among the descendants
of females V-18 and V-57 is 15% and 16%, respectively
(these females are not designated in fig. 1). Female V-21
gave rise to two branches if one distinguishes the de-
scendants from her two marriages, and the approximate
penetrance values are 33% (which includes the H1 and
H2 branches; see fig. 1 and the results given below) and
20%. Therefore, in the comparison of branches of sim-
ilar size, the low-penetrance branches stand out clearly,
a result that argues against severe bias.
The evidence for low-penetrance branching is further
supported when the results for all four branches are
pooled and the results are compared with the overall
penetrance in the matrilineal pedigree. Thus, there is 1
affected male among the total of 106 males in the four
branches (a penetrance of ∼1%), whereas there are∼200
affected males among a total of ∼800 in the medium-
and high-penetrance branches of the TAS1 pedigree (an
overall penetrance of ∼25%). The actual difference in
penetrance values is larger, because the estimate of 25%
is not adjusted upward to account for those males who
are !30 years of age.
There may also be high-penetrance branches, al-
though, because of the small number of family members
in these branches, this possibility is less robust. There
are in the TAS1 family two small branches (designated
“H1” and “H2”) in which the penetrance was unusually
high. Thus, in the small H2 branch, 12 (67%) of 18
males were affected. Only 3 (30%) of 10 males were
affected in branch H1, but 5 (25%) of 20 females were
also affected.
The most obvious explanation for the low-penetrance
branches in the TAS1 pedigree is heteroplasmy of the
11778 mutation in the early generations. The pathogenic
mutation could have segregated into both homoplasmic
mutant and homoplasmic wild-type branches (this sit-
uation has occurred in the QLD2 11778 LHON family,
as described in Howell et al. 1995, p. 298). To test this
possibility, we analyzed DNA from seven members of
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low-penetrance branches and from two members of
high-penetrance branches. In brief, our approach in-
volves both PCR amplification of short (300–400 bp)
spans of the mitochondrial genome and subsequent se-
quencing analysis of multiple, independent M13 clones
that contain the mtDNA insert (e.g., see Howell et al.
1991, 1995). For these nine TAS1 LHON family mem-
bers, the DNA sequences of 1400 independent mtDNA
inserts that contained a short segment of the ND4 gene
were determined. It was found that all of them carried
the 11778 mutant allele. Furthermore, restriction-site as-
says of another 40 TAS1 LHON family members have
confirmed that the 11778 primary mutation is homo-
plasmic in all family members (data not shown). Fur-
thermore, tissue-distribution studies indicate that mu-
tation load in blood either reflects the levels in other
tissues (Juvonen et al. 1997) or is lower than those in
other tissues (Howell et al. 1994). Thus, the cumulative
results show that the low penetrance in some branches
of the TAS1 family is not due to segregational loss (or
reversion) of the 11778 mutant allele.
We then extended the sequencing analysis to search
for a second site, or suppressor, mitochondrial gene
mutation. Family members from the low-penetrance
branches may carry a secondary mutation that pheno-
typically suppresses the pathogenic effects of the 11778
mutation. For example, a suppressor mutation might
have arisen in a common maternal ancestor, persisted in
the heteroplasmic state for several generations, and even-
tually become fixed in some branches of the matrilineal
pedigree, but not in others, as a result of segregation in
the germ line. There are results that suggest the occur-
rence of mitochondrial suppressor mutations. Thus, the
QLD1 LHON family carries, at nucleotide 4160 of the
ND1 gene, a mutation that is associated with the severe
neurological abnormalities (Howell 1994). A putative
intragenic suppressor mutation at nucleotide 4136 has
arisen in one small branch (Howell et al. 1991). In ad-
dition, Hammans et al. (1995) and El Meziane et al.
(1998) have reported suppressor mutations of a path-
ogenic tRNA mutation.
Six overlapping, PCR-amplified fragments of the mi-
tochondrial genome, which cumulatively spanned nu-
cleotides 10435–12373 (numbered according to Ander-
son et al. 1981), were analyzed for each of the five TAS1
LHON family members. This 1.9-kb span of themtDNA
included the 3′ half of the tRNAArg gene, the ND4L gene
(nucleotides 10470–10763), the ND4 gene (nucleotides
10760–12137), a cluster of three butt-joined tRNA
genes (tRNAHis, tRNASer[AGY], and tRNALeu[CUN]), and the
first 36 nucleotides of the ND5 gene. Multiple (x10)
independent clones were sequenced for each of the six
mtDNA fragments and for each family member, in an
effort to detect heteroplasmic mutations. No new se-
quence changes were detected in any of the five family
members. The sequence of this span of themitochondrial
genome was identical for all family members, including
the presence of a rare, silent polymorphism at nucleotide
11788. Among the 1200 pedigrees (control and LHON)
that we have screened, this polymorphism thus far is
unique to the TAS1 LHON family, and we have thus
verified that the members of the low-penetrance
branches are indeed of the correct maternal lineage.
Finally, we have begun a wider search for an intergenic
mitochondrial suppressor mutation. The first fragment
that we analyzed, which spanned nucleotides 3286–
3564, included the site of the primary LHONmutation,
at nucleotide 3460; the second fragment that we ana-
lyzed, which spanned nucleotides 4027–4294, included
the sites of both the pathogenic mutation, at nucleotide
4160, and the putative suppresser mutation, at nucle-
otide 4136, as well as that of the putative secondary
LHONmutation, at nucleotide 4216 (Johns and Berman
1991); the third fragment that we analyzed, which
spanned nucleotides 14381–14699, included the site of
the primary LHON mutation, at nucleotide 14484, and
several other sites at which pathogenic mutations have
been identified (see the discussion in Howell et al. 1998).
The TAS1 mtDNA does not carry any of the aforemen-
tioned “accessory” LHON mutations, and there were
no new mutations in these regions of the mitochondrial
genome, among any of the low- and high-penetrance
family members who were analyzed.
In addition to the results for the TAS1 LHON family,
there are other examples of low-penetrance branches in
LHON families. We have also observed that low-pen-
etrance branches apparently occur in the large 14484-
mutation TAS2 LHON family (D. A. Mackey, unpub-
lished data), which comprises ∼700 maternally related
individuals (Mackey and Buttery 1992). As one example,
none of the 28 males (x30 years of age) who have
descended from female VII-22 have lost vision (authors’
unpublished data). We are continuing our analysis of the
TAS2 pedigree, because penetrance in 14484-mutation
LHON families is more difficult to quantitate with ac-
ceptable certainty, because of the high frequency of vi-
sion recovery. It becomes more difficult to distinguish a
true lack of vision loss from a mild vision loss and rapid
recovery, particularly when one must rely, in part, on
second-hand information about vision status in relatives.
Inspection of pedigree data in the literature also suggests
the presence of low-penetrance branches that have been
unremarked until now (see, especially, pedigrees XX and
XXVIII in van Senus 1963).
Overall, therefore, it appears that low-penetrance
branching in LHON matrilineal pedigrees is a biologi-
cally “real” phenomenon. One explanation is that the
low-penetrance branches are real but that there are dif-
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ferent epigenetic and/or environmental factors that
lower the penetrance in each branch. Alternatively, low-
penetrance branching may be due to the introduction of
a nuclear genetic suppressor locus. This explanation,
however, is problematic, because each low-penetrance
branch involves a number of outbreeding events (i.e.,
marriages), which should act to “localize” any effects of
a dominantly acting nuclear locus to one or two gen-
erations. Third, low-penetrance branching may be
caused by amitochondrial suppressor locus, but one that
lies in a mitochondrial genome region that was not se-
quenced in the experiments that are reported here. Thus
far, we have sequenced (a) only approximately one-third
of the mitochondrial genome that encodes the seven su-
bunits of complex I (NADH-ubiquinone oxidoreduc-
tase) or (b) only approximately one-fifth of the entire
coding region.
The suggestion of a mitochondrial mutation that de-
creases penetrance in the TAS1 LHON family converges
with the related issue of phylogenetic clustering. Both
the 11778 mutation and, especially, the 14484 LHON
mutation occur more often in European haplogroup J
mtDNA backgrounds than would be expected on a ran-
dom basis (although the TAS1 mtDNA haplotype does
not belong to this haplogroup). There is debate over the
basis of this clustering phenomenon (see the discussion
in Howell et al. 1995 and Mackey et al. 1998), but
Brown et al. (1997) and Torroni et al. (1997) have con-
cluded that LHON penetrance is influenced by the
mtDNA background in which the pathogenic mutations
arise. Thus, the apparent underrepresentation of some
mtDNA haplotypes among LHON patients is caused by
low penetrance, because of one or more sequence
changes within these mtDNAs. As a consequence of the
lower penetrance, fewer pedigrees come to the attention
of clinicians. Within the haplotype J mtDNA, the site(s)
that influences penetrance has not been identified, but
the basic premise is similar to that proposed here to
explain the presence of low-penetrance branches within
a single LHON pedigree. In summary, the present results
underscore both the complex etiology of LHON and the
fact that the identification of the secondary etiologic fac-
tors is a prerequisite for a further understanding of this
disorder.
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Double Heterozygotes for the Ashkenazi Founder
Mutations in BRCA1 and BRCA2 Genes
To the Editor:
Three Jewish founder mutations, 185delAG and
5382insC in BRCA1 and 6174delT in BRCA2 genes,
have been identified in breast cancer (BC) and ovarian
cancer (OC) Ashkenazi patients. In the Ashkenazi gen-
eral population, the carrier frequencies of these founder
mutations are 1% for 185delAG (Struewing et al. 1996),
0.13% for 5382insC, and 1.35% for 6174delT (Roa et
al. 1996; Oddoux et al. 1996). Given these high pop-
ulation frequencies, one would expect to find individuals
homozygous for the mutations 185delAG/185delAG,
6174delT/6174delT, and 5382insC/5382insC, com-
pound heterozygous for 185delAG/5382insC, or double
heterozygous for 185delAG/6174delT or 5382insC/
6174delT, provided the individuals are viable. The effect
of two mutations in a single individual is important both
for an understanding of the mode of action and inter-
action between the BRCA1 and BRCA2 genes and for
appropriate genetic counseling. To date, two double het-
erozygous patients (185delAG/6174delT; Ramus et al.
1997; Gershoni-Baruch et al. 1997) and one patient ho-
mozygous for a mutation in exon 11 of the BRCA1 gene
(Boyd et al. 1995) have been reported.
By pooling results from four cancer/genetics centers
in Israel, we have analyzed ∼1,500 BC/OC Ashkenazi
patients. All subjects received genetic counseling and
signed informed consent forms in compliance with in-
stitutional ethics committees (institutional review
boards). Each patient was tested for the three Ashkenazi
founder mutations: in BRCA1, the mutations 185delAG
and 5382insC, and in BRCA2, the mutation 6174delT
(Abeliovich et al. 1997; Levy-Lahad et al. 1997; Bruchim
Bar-Sade et al. 1998). Four patients were found to be
double heterozygotes. Summaries of their clinical status
and pedigrees are presented in table 1 and figure 1.
Patient 1 is an Ashkenazi mother of two children who
was diagnosed with unilateral breast cancer at the age
of 38 years. Her family history was positive for both
OC, with which her mother was diagnosed at the age
of 50 years, and breast cancer, with which her paternal
aunt was diagnosed at the age of 60 years and her daugh-
ter at the age of 35 years. Her paternal grandfather had
lung cancer at the age of 45 years. A test for 185delAG/
6174delT in her father revealed neither mutation; DNA
could not be retrieved from the paraffin block of her
mother. Analysis of the polymorphic markers D17S855,
D17S1322, D17S1323, D9S55, and D11S1337 in the
father and in Patient 1 confirmed paternity. It was thus
